Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method
BackgroundSenescence have emerged as potential factors of lung cancer risk based on findings from many studies. However, the underlying pathogenesis of lung cancer caused by senescence is not clear. In this study, we try to explain the potential pathogenesis between senescence and lung cancer throug...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1255889/full |
| _version_ | 1797689994893066240 |
|---|---|
| author | Xiaolu Fang Deyang Liu Jianzhong Zhao Xiaojia Li Ting He Baishan Liu |
| author_facet | Xiaolu Fang Deyang Liu Jianzhong Zhao Xiaojia Li Ting He Baishan Liu |
| author_sort | Xiaolu Fang |
| collection | DOAJ |
| description | BackgroundSenescence have emerged as potential factors of lung cancer risk based on findings from many studies. However, the underlying pathogenesis of lung cancer caused by senescence is not clear. In this study, we try to explain the potential pathogenesis between senescence and lung cancer through proteomics and metabonomics. And try to find new potential therapeutic targets in lung cancer patients through network mendelian randomization (MR).MethodsThe genome-wide association data of this study was mainly obtained from a meta-analysis and the Transdisciplinary Research in Cancer of the Lung Consortium (TRICL), respectively.And in this study, we mainly used genetic complementarity methods to explore the susceptibility of aging to lung cancer. Additionally, a mediation analysis was performed to explore the potential mediating role of proteomics and metabonomics, using a network MR design.ResultsGNOVA analysis revealed a shared genetic structure between HannumAge and lung cancer with a significant genetic correlation estimated at 0.141 and 0.135, respectively. MR analysis showed a relationship between HannumAge and lung cancer, regardless of smoking status. Furthermore, genetically predicted HannumAge was consistently associated with the proteins C-type lectin domain family 4 member D (CLEC4D) and Retinoic acid receptor responder protein 1 (RARR-1), indicating their potential role as mediators in the causal pathway.ConclusionHannumAge acceleration may increase the risk of lung cancer, some of which may be mediated by CLEC4D and RARR-1, suggestion that CLEC4D and RARR-1 may serve as potential drug targets for the treatment of lung cancer. |
| first_indexed | 2024-03-12T01:54:13Z |
| format | Article |
| id | doaj.art-6459b5ba836945269f7c80026bfb2956 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-12T01:54:13Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-6459b5ba836945269f7c80026bfb29562023-09-08T07:26:59ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-09-011410.3389/fendo.2023.12558891255889Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity methodXiaolu Fang0Deyang Liu1Jianzhong Zhao2Xiaojia Li3Ting He4Baishan Liu5Department of Clinical Laboratory, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Rehabilitation Medicine, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Clinical Laboratory, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Respiratory, Jiulongpo District People’s Hospital of Chongqing, Chongqing, ChinaDepartment of Respiratory, Jiulongpo District People’s Hospital of Chongqing, Chongqing, ChinaDepartment of Respiratory, Jiulongpo District People’s Hospital of Chongqing, Chongqing, ChinaBackgroundSenescence have emerged as potential factors of lung cancer risk based on findings from many studies. However, the underlying pathogenesis of lung cancer caused by senescence is not clear. In this study, we try to explain the potential pathogenesis between senescence and lung cancer through proteomics and metabonomics. And try to find new potential therapeutic targets in lung cancer patients through network mendelian randomization (MR).MethodsThe genome-wide association data of this study was mainly obtained from a meta-analysis and the Transdisciplinary Research in Cancer of the Lung Consortium (TRICL), respectively.And in this study, we mainly used genetic complementarity methods to explore the susceptibility of aging to lung cancer. Additionally, a mediation analysis was performed to explore the potential mediating role of proteomics and metabonomics, using a network MR design.ResultsGNOVA analysis revealed a shared genetic structure between HannumAge and lung cancer with a significant genetic correlation estimated at 0.141 and 0.135, respectively. MR analysis showed a relationship between HannumAge and lung cancer, regardless of smoking status. Furthermore, genetically predicted HannumAge was consistently associated with the proteins C-type lectin domain family 4 member D (CLEC4D) and Retinoic acid receptor responder protein 1 (RARR-1), indicating their potential role as mediators in the causal pathway.ConclusionHannumAge acceleration may increase the risk of lung cancer, some of which may be mediated by CLEC4D and RARR-1, suggestion that CLEC4D and RARR-1 may serve as potential drug targets for the treatment of lung cancer.https://www.frontiersin.org/articles/10.3389/fendo.2023.1255889/fullsenescencelung cancerNetwork Mendelian randomizationproteomics and metabolomicstherapeutic targetgenetic complementarity method senescence |
| spellingShingle | Xiaolu Fang Deyang Liu Jianzhong Zhao Xiaojia Li Ting He Baishan Liu Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method Frontiers in Endocrinology senescence lung cancer Network Mendelian randomization proteomics and metabolomics therapeutic target genetic complementarity method senescence |
| title | Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method |
| title_full | Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method |
| title_fullStr | Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method |
| title_full_unstemmed | Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method |
| title_short | Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method |
| title_sort | using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer genetic complementarity method |
| topic | senescence lung cancer Network Mendelian randomization proteomics and metabolomics therapeutic target genetic complementarity method senescence |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1255889/full |
| work_keys_str_mv | AT xiaolufang usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod AT deyangliu usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod AT jianzhongzhao usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod AT xiaojiali usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod AT tinghe usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod AT baishanliu usingproteomicsandmetabolomicstoidentifytherapeutictargetsforsenescencemediatedcancergeneticcomplementaritymethod |